VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Billy Connolly writes moving letters to grandchildren as he battles Parkinson’s
Comedian to leave letters behind for grandchildren after his death
2 days ago
Improving access to Parkinson’s disease resources on Amazon’s Alexa
US non-profit Parkinson’s Foundation has announced a new partnership with Amazon’s smart speaker Alexa to help more people access resources related to Parkinson’s disease. As part of the collaboration, Alexa-enabled devices will answer questions about Parkinson’s disease in English and Spanish, citing sources from the Parkinson’s Foundation. The educational initiative is aimed at people with the condition, their care partners, family and friends and health professionals – and will help them find information on topics including Covid-19 and Parkinson’s, symptoms and early signs of the condition, and more. John L Lehr, president and CEO of the Parkinson’s Foundation, said: “We are thrilled to work with Amazon to move into this exciting world of smart speakers to help even more people gain access to the information about Parkinson’s disease they need most. Our hope is that this partnership will help us further reach and better support the Parkinson’s disease community throughout every…
Scientists at MIT uncover new clues about Parkinson’s disease
Neuroscientists at Massachusetts Institute of Technology (MIT), US, have developed new tools that could improve understanding of Parkinson’s disease. As part of a study, published in Science Advances, the tools were used on animals to investigate the relationship between two types of signals that are disrupted in Parkinson’s – dopamine signalling and beta-band oscillations (coordinated waves of electrical activity in the brain). The scientists found that while the animals performed certain tasks, beta-band oscillations increased while dopamine signalling declined in particular parts of the brain. Factors including an animal’s past experience and the reward value of a task also impacted the relationship between the two signals. Helen Schwerdt, a research scientist at MIT, said: “Considering electrical signals side by side with chemical signals is really important to understand how the brain works.” Ann Graybiel, a professor at MIT, added: “As these methods in neuroscience become more and more precise and…
People with Parkinson’s disease have a higher risk of dying from Covid-19, study finds
A new database study of around 80,000 Covid-19 patients has found that those living with Parkinson’s disease have a 30% higher risk of dying from the virus than those without the condition. The study – conducted by researchers at the University of Iowa Health Care, US – identified that Covid-19 patients with Parkinson’s disease were generally older, more likely to be male and less likely to be African American. As these factors could also affect the risk of death from Covid-19, the researchers adjusted their statistical models to account for differences in sex, age and race and found a significantly higher risk of dying from Covid-19 in the group of patients with Parkinson’s disease. Lead researcher Dr Nandakumar Narayanan said: “We recognise the limitations of this study; it is retrospective data from a single database, but we are confident that these data show that Parkinson’s disease is [an] independent risk factor…